We’re looking back at day 2 of the ATTD 2026 scientific programme. Welcome to this EASD e-Learning Newsflash with our key highlights. Expanding the focus beyond glycaemia, Lia Bally co-chaired a session on managing overweight and obesity in type 1 diabetes – in which she also presented. The prevalence of overweight and obesity among people with type 1 diabetes is really mirroring the trends that we see in the general population. So overweight prevalence is approximately 40 to 45 % and obesity 15 to 35 %. There are specific challenges for this population, especially if we talk about incretin therapies, because people with type 1 diabetes have heightened vulnerability to drug-related risks, for example, hypoglycaemia when insulin is not adequately tapered, or also DKA when there is an extreme negative energy balance, especially if other factors that predispose to DKA factor in. Diabetes technology can greatly help to manage these specific challenges in type 1 diabetes. First of all, AID systems help to accommodate the changing insulin requirements. If you think about safety, the ketone sensors down the line will greatly help to mitigate DKA. And also for personalised incretin drug dosing and lifestyle management technology can make a huge difference. Continuing our focus on type 1 diabetes, moderated by ATTD co-chair Tadej Battelino, the IDF Europe Symposium explored how to turn vision into reality moving from detection to a cure. IDF Europe has the ultimate goal of bringing latest innovations to people living with diabetes as soon as possible. The joint symposium would like to show first the guidance we try to give on how to do this directly to the policymakers. One of the very important focuses we have is the screening for type 1 diabetes. Italy in the European Union is leading this by implementing a law, and there are other examples following up, like Portugal. It’s a group of initiatives that hopefully will lead to a universal population based screening in European countries. The idea of course is first to prevent diabetic ketoacidosis, because initial DKA actually may have consequences on cognitive development. And the second of course is to get people that will develop diabetes at stage 2, where interventions are available, or to enrol them into clinical trials where they can potentially benefit and postpone at least the beginning of stage 3. Last but not least, I’m delighted that EASD President Francesco Giorgino took a moment to share with us his personal scientific highlights of the day. We have already quite substantial evidence that CGM is of benefit for people with diabetes if they are treated with insulin, especially multiple daily injections of insulin. We have less evidence for people that are, for example, treated with only basal insulin. And I listened to a very interesting trial, FreeDM2, and I think it’s quite impressive to see the difference in HbA1c, the change from baseline. Another interesting takeaway is one sensor that can provide both informations, continuous glucose monitoring and continuous ketone monitoring. I can see a lot of potential interesting applications of this technology, actually, so for preventing DKA, diabetic ketoacidosis, but also looking at some special populations with diabetes, people that for example are pregnant or people that are hospitalised, have a major illness, technology is really opening new horizons with new challenges for science, but also I think new opportunities for both science and care. Speaking of new opportunities, we’re still early in the conference season. What important updates are going to await us at the EASD Annual Meeting in Milano? There will be an opportunity to further focus on diabetes, type 1, type 2 diabetes, other forms of diabetes, also the comorbidities of diabetes, which are unfortunately numerous. It’s an opportunity to review the tools we have available today, especially in the field of multi-agonists, that are of course able to provide a number of benefits, metabolic and also not metabolic in terms of organ protection. And also I have to announce that we will release the new version of the ADA/EASD Consensus for treatment of people with type 2 diabetes. So, this is a major achievement. By the way, let me also remind that the deadline for abstract submission is April 1st, so still some time to prepare abstracts to be sent and to of course have an opportunity to present science results and new data in Milan at EASD 2026. That's it for today. Join us tomorrow for our final highlights from ATTD 2026 – with Amit Gupta, Lutz Heinemann and EASD past president Chantal Mathieu.